BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34279414)

  • 21. Zinc(II) complexes with dithiocarbamato derivatives: structural characterisation and biological assays on cancerous cell lines.
    Nagy EM; Sitran S; Montopoli M; Favaro M; Marchiò L; Caparrotta L; Fregona D
    J Inorg Biochem; 2012 Dec; 117():131-9. PubMed ID: 23085593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ru(III) anticancer agents with aromatic and non-aromatic dithiocarbamates as ligands: Loading into nanocarriers and preliminary biological studies.
    Scintilla S; Brustolin L; Gambalunga A; Chiara F; Trevisan A; Nardon C; Fregona D
    J Inorg Biochem; 2016 Dec; 165():159-169. PubMed ID: 27889069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative solution equilibrium and structural studies of half-sandwich ruthenium(II)(η
    Poljarević JM; Tamás Gál G; May NV; Spengler G; Dömötör O; Savić AR; Grgurić-Šipka S; Enyedy ÉA
    J Inorg Biochem; 2018 Apr; 181():74-85. PubMed ID: 29407910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticancer Activity and Apoptosis Induction of Gold(III) Complexes Containing 2,2'-Bipyridine-3,3'-dicarboxylic Acid and Dithiocarbamates.
    Alhoshani A; Sulaiman AAA; Sobeai HMA; Qamar W; Alotaibi M; Alhazzani K; Monim-Ul-Mehboob M; Ahmad S; Isab AA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34209921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic Ruthenium(II) Complexes Containing a Dangling Pyridine: Selectivity for Diseased Cells Mediated by pH-Dependent DNA Binding.
    Sangeetha S; Murali M
    Inorg Chem; 2022 Feb; 61(6):2864-2882. PubMed ID: 35099196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, Synthesis and Pharmacological Evaluation of Three Novel Dehydroabietyl Piperazine Dithiocarbamate Ruthenium (II) Polypyridyl Complexes as Potential Antitumor Agents: DNA Damage, Cell Cycle Arrest and Apoptosis Induction.
    Wang H; Wei J; Jiang H; Zhang Y; Jiang C; Ma X
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33800091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
    Lazarević T; Rilak A; Bugarčić ŽD
    Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hetero-Bis-Conjugation of Bioactive Molecules to Half-Sandwich Ruthenium(II) and Iridium(III) Complexes Provides Synergic Effects in Cancer Cell Cytotoxicity.
    Biancalana L; Kostrhunova H; Batchelor LK; Hadiji M; Degano I; Pampaloni G; Zacchini S; Dyson PJ; Brabec V; Marchetti F
    Inorg Chem; 2021 Jul; 60(13):9529-9541. PubMed ID: 34156246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lysosome-targeted ruthenium(II) complexes induce both apoptosis and autophagy in HeLa cells.
    Pan NL; Liao JX; Huang MY; Zhang YQ; Chen JX; Zhang ZW; Yang ZX; Long XE; Wu XT; Sun J
    J Inorg Biochem; 2022 Apr; 229():111729. PubMed ID: 35066350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
    Golbaghi G; Pitard I; Lucas M; Haghdoost MM; de Los Santos YL; Doucet N; Patten SA; Sanderson JT; Castonguay A
    Eur J Med Chem; 2020 Feb; 188():112030. PubMed ID: 31945643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of aromaticity on anticancer activity of polypyridyl ruthenium(II) complexes: synthesis, structure, DNA/protein binding, lipophilicity and anticancer activity.
    Čanović P; Simović AR; Radisavljević S; Bratsos I; Demitri N; Mitrović M; Zelen I; Bugarčić ŽD
    J Biol Inorg Chem; 2017 Oct; 22(7):1007-1028. PubMed ID: 28695374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bifunctional ruthenium(ii) polypyridyl complexes of curcumin as potential anticancer agents.
    Li S; Xu G; Zhu Y; Zhao J; Gou S
    Dalton Trans; 2020 Jul; 49(27):9454-9463. PubMed ID: 32598409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ru
    Lenis-Rojas OA; Robalo MP; Tomaz AI; Carvalho A; Fernandes AR; Marques F; Folgueira M; Yáñez J; Vázquez-García D; López Torres M; Fernández A; Fernández JJ
    Inorg Chem; 2018 Nov; 57(21):13150-13166. PubMed ID: 30339386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of the pharmacological profiles of dinuclear metal complexes as novel, potent and selective cytotoxic agents against ras-transformed cells.
    Bostancıoğlu RB; Koparal AT; Benkli K
    Environ Toxicol Pharmacol; 2014 May; 37(3):897-906. PubMed ID: 24694919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Maltol-Containing Ruthenium Polypyridyl Complex as a Potential Anticancer Agent.
    Notaro A; Jakubaszek M; Koch S; Rubbiani R; Dömötör O; Enyedy ÉA; Dotou M; Bedioui F; Tharaud M; Goud B; Ferrari S; Alessio E; Gasser G
    Chemistry; 2020 Apr; 26(22):4997-5009. PubMed ID: 32065454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and anti-cancer activity of bis-amino-phosphine ligand and its ruthenium(II) complexes.
    Engelbrecht Z; Roberts KE; Hussan A; Amenuvor G; Cronjé MJ; Darkwa J; Makhubela BCE; Sitole L
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127492. PubMed ID: 32791194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unprecedented inhibition of P-gp activity by a novel ruthenium-cyclopentadienyl compound bearing a bipyridine-biotin ligand.
    Côrte-Real L; Karas B; Gírio P; Moreno A; Avecilla F; Marques F; Buckley BT; Cooper KR; Doherty C; Falson P; Garcia MH; Valente A
    Eur J Med Chem; 2019 Feb; 163():853-863. PubMed ID: 30579125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
    Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
    Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward the selective delivery of chemotherapeutics into tumor cells by targeting peptide transporters: tailored gold-based anticancer peptidomimetics.
    Kouodom MN; Ronconi L; Celegato M; Nardon C; Marchiò L; Dou QP; Aldinucci D; Formaggio F; Fregona D
    J Med Chem; 2012 Mar; 55(5):2212-26. PubMed ID: 22309237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis, characterization and biological evaluation of cationic organoruthenium(ii) fluorene complexes: influence of the nature of the counteranion.
    Haghdoost MM; Golbaghi G; Guard J; Sielanczyk S; Patten SA; Castonguay A
    Dalton Trans; 2019 Sep; 48(35):13396-13405. PubMed ID: 31432885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.